Multi-Peptide Cmv-Modified Vaccinia Ankara Vaccine
Hematopoietic And Lymphoid System Neoplasm
Explore 134 assets in Hematopoietic And Lymphoid System Neoplasm →Floatz Rating
CCC54/100
Confidence
Indicative
Sponsor
City of Hope Medical Center
Modality
vaccine
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07020533CT.gov A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant | — | Recruiting | — | — | — |
NCT06059391CT.gov CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hematopoietic And Lymphoid System Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Multi-Peptide Cmv-Modified Vaccinia Ankara Vaccine (this asset) | City of Hope Medical Center | P2 | CCC · 54 |
| Adriamycin | OHSU Knight Cancer Institute | P4 | BBB |
| Teclistamab | Janssen Pharmaceutical K.K. | P2 | BB |
| Dexasone | City of Hope Medical Center | P3 | BB |
| Cyclophosphamide | National Cancer Institute (NCI) | P3 | BB |
| Bortezomib | OHSU Knight Cancer Institute | P4 | BB |
| Allogeneic, Ex Vivo Expanded, Umbilical Cord Blood-Derived Hematopoietic Cd133+ Progenitor Cells- Cultured Fraction (Cf) | Gamida Cell ltd | P3 | BB |
| Etoposide | Ciusss de L'Est de l'Île de Montréal | P2 | BB |
| Pembrolizumab | Vividion Therapeutics, Inc. | P3 | BB |
+42 more in the Hematopoietic And Lymphoid System Neoplasm cohort
Other indications for Multi-Peptide Cmv-Modified Vaccinia Ankara Vaccine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Hematopoietic And Lymphoid Cell Neoplasm | — | P2 | B · 60 |
| Chronic Myeloid Leukemia | — | P2 | CCC · 54 |
| Acute Lymphoblastic Leukemia | — | P2 | CCC · 54 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Multi-Peptide Cmv-Modified Vaccinia Ankara Vaccine in Hematopoietic And Lymphoid System Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 9, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/multi-peptide-cmv-modified-vaccinia-ankara-vaccine-hematopoietic-and-lymphoid-system-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →